Gender and Women's Health Unit, Centre for Health Equity, School of Population and Global Health, University of Melbourne, Carlton, VIC, Australia.
Maternal, Child, and Adolescent Health Programme, Burnet Institute, Melbourne, VIC, Australia.
BJOG. 2022 Feb;129(3):379-391. doi: 10.1111/1471-0528.16913. Epub 2021 Oct 4.
Hypertensive disorders account for 14% of global maternal deaths. Magnesium sulphate (MgSO ) is recommended for prevention and treatment of pre-eclampsia/eclampsia. However, MgSO remains underused, particularly in low- and middle-income countries (LMICs).
This qualitative evidence synthesis explores perceptions and experiences of healthcare providers, administrators and policy-makers regarding factors affecting use of MgSO to prevent or treat pre-eclampsia/eclampsia.
We searched MEDLINE, EMBASE, Emcare, CINAHL, Global Health and Global Index Medicus, and grey literature for studies published between January 1995 and June 2021.
Primary qualitative and mixed-methods studies on factors affecting use of MgSO in healthcare settings, from the perspectives of healthcare providers, administrators and policy-makers, were eligible for inclusion.
We applied a thematic synthesis approach to analysis, using COM-B behaviour change theory to map factors affecting appropriate use of MgSO .
We included 22 studies, predominantly from LMICs. Key themes included provider competence and confidence administering MgSO (attitudes and beliefs, complexities of administering, knowledge and experience), capability of health systems to ensure MgSO availability at point of use (availability, resourcing and pathways to care) and knowledge translation (dissemination of research and recommendations). Within each COM-B domain, we mapped facilitators and barriers to physical and psychological capability, physical and social opportunity, and how the interplay between these domains influences motivation.
These findings can inform policy and guideline development and improve implementation of MgSO in clinical care. Such action is needed to ensure this life-saving treatment is widely available and appropriately used.
Global qualitative review identifies factors affecting underutilisation of MgSO for pre-eclampsia and eclampsia.
高血压疾病占全球产妇死亡人数的 14%。硫酸镁(MgSO)被推荐用于预防和治疗子痫前期/子痫。然而,MgSO 的使用率仍然较低,特别是在中低收入国家(LMICs)。
本定性证据综合研究探讨了医疗保健提供者、管理人员和政策制定者对影响使用 MgSO 预防或治疗子痫前期/子痫的因素的看法和经验。
我们检索了 MEDLINE、EMBASE、Emcare、CINAHL、全球卫生和全球索引医学,并检索了 1995 年 1 月至 2021 年 6 月期间发表的灰色文献,以获取有关影响在医疗保健环境中使用 MgSO 的因素的研究。
符合条件的研究为主要定性和混合方法研究,从医疗保健提供者、管理人员和政策制定者的角度探讨了影响 MgSO 使用的因素。
我们采用主题综合分析方法进行分析,使用 COM-B 行为改变理论来映射影响 MgSO 合理使用的因素。
我们纳入了 22 项研究,主要来自 LMICs。主要主题包括提供者管理 MgSO 的能力和信心(态度和信念、管理的复杂性、知识和经验)、卫生系统确保在使用点获得 MgSO 的能力(可用性、资源和护理途径)和知识转化(研究和建议的传播)。在每个 COM-B 领域内,我们绘制了对身体和心理能力、身体和社会机会的促进因素和障碍,以及这些领域之间的相互作用如何影响动机。
这些发现可以为政策和指南制定提供信息,并改善 MgSO 在临床护理中的实施。需要采取行动,以确保这种救命治疗方法广泛可用并得到适当使用。
全球定性综述确定了影响子痫前期和子痫中 MgSO 利用率低的因素。